Why the study?
Hypertension is a proposed risk factor for renal cell cancer and renin-angiotensin system inhibitors have been linked to improved prognosis, prompting exploration of renal cell cancer survival among antihypertensive drug users.
Does the use of antihypertensive medications, specifically ACE-inhibitors and ARBs, improve survival in patients with renal cell cancer?
Population
13,873 participants with RCC diagnosed between 1995-2012 in Finland
Comparison
Antihypertensive medication users vs non-users
Design
National registry-based cohort study
Authors
Loading...
Antihypertensive use after RCC diagnosis may improve survival; leaves open whether RAS inhibitors add benefit beyond blood pressure control.
Does the use of antihypertensive medications, specifically ACE-inhibitors and ARBs, improve survival in patients with renal cell cancer?
High-dose use of ACE-inhibitors and ARBs is associated with improved renal cell cancer-specific survival, suggesting a potential benefit of targeting the renin-angiotensin system in RCC patients.
Eskelinen et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: